NCT06361537: An ongoing trial by Octapharma
This trial is ongoing. It must report results 1 year, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06361537 |
|---|---|
| Title | Prospective, Multicenter, Randomized, Double-blind, Parallel Group, Placebo- Controlled, Efficacy and Safety Phase 3 Study of an Intravenous Human Plasma- Derived C1 Esterase Inhibitor (C1-INH) Concentrate in Participants With Congenital C1-INH Deficiency for the Treatment and Pre-procedure Prevention of Acute Hereditary Angioedema Attacks |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 30, 2024 |
| Completion date | Dec. 31, 2026 |
| Required reporting date | Dec. 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 15, 2026 |
| Days late | None |